Glutamate carboxypeptidase II

From WikiMD's Medical Encyclopedia

Revision as of 21:21, 19 May 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

File:CommonInhibitors.gif

Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is an enzyme that in humans is encoded by the FOLH1 gene. This enzyme is a type II transmembrane glycoprotein and is involved in the hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) to N-acetylaspartate (NAA) and glutamate.

Function[edit]

Glutamate carboxypeptidase II plays a crucial role in the central nervous system by regulating the levels of the neurotransmitter glutamate. Glutamate is an important excitatory neurotransmitter, and its dysregulation is associated with various neurological disorders, including Alzheimer's disease, schizophrenia, and epilepsy. GCPII is also expressed in the prostate gland, where it is referred to as prostate-specific membrane antigen (PSMA). PSMA is a marker for prostate cancer and is used in diagnostic imaging and targeted therapy.

Structure[edit]

GCPII is a zinc-dependent metallopeptidase and belongs to the M28 family of peptidases. The enzyme consists of a large extracellular domain, a single transmembrane domain, and a short intracellular tail. The extracellular domain contains the active site, which binds to zinc ions essential for its enzymatic activity.

Clinical Significance[edit]

GCPII is a target for the diagnosis and treatment of prostate cancer. PSMA expression is significantly upregulated in prostate cancer cells compared to normal prostate tissue, making it a valuable biomarker. Radiolabeled PSMA inhibitors are used in positron emission tomography (PET) imaging to detect prostate cancer metastases. Additionally, PSMA-targeted therapies, such as PSMA-targeted radioligand therapy, are being developed to treat advanced prostate cancer.

Research[edit]

Research on GCPII is ongoing to better understand its role in neurological disorders and to develop new therapeutic strategies. Inhibitors of GCPII are being investigated for their potential to modulate glutamate levels in the brain and treat conditions like neuropathic pain and cognitive disorders.

See Also[edit]

References[edit]

External Links[edit]


Stub icon
   This article is a enzyme-related stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.